Anti-TRIP12 Antibody
Catalog No : IGX-42962
237.00€
175.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Description | E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair (PMID:19028681, PMID:22884692). Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins (PMID:19028681). Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes (PMID:22884692). In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress (PMID:20208519). In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation (PMID:20208519). Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A (PMID:20208519). Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation (PMID:18627766). Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins (PMID:20829358). Mediates ubiquitination of ASXL1: following binding to N6-methyladenosine methylated DNA, ASXL1 is ubiquitinated by TRIP12, leading to its degradation and subsequent inactivation of the PR-DUB complex (PMID:30982744). | ||
|---|---|---|---|
| Other names | E3 ubiquitin-protein ligase TRIP12, EC 2.3.2.26, E3 ubiquitin-protein ligase for Arf, ULF, HECT-type E3 ubiquitin transferase TRIP12, Thyroid receptor-interacting protein 12, TR-interacting protein 12, TRIP-12, TRIP12, KIAA0045 ULF | ||
| Cellular localization | Nucleus, Nucleoplasm | ||
| Research area | Epigenetics & Nuclear Signaling | ||
| Note | This product is for research purpose only, not for use in diagnostics or as therapeutics. | ||
| Uniprot ID | Q14669 | ||
| Product name | Anti-TRIP12 Antibody | ||
|---|---|---|---|
| Catalog No | IGX-42962 | ||
| Supplier’s Catalog No | IGX-42962 | ||
| Supplier | ImuGeX | ||
| Host species | Rabbit | ||
| Species reactivity | Human | ||
| Applications | ELISA, IHC | ||
| Recommended dilutions | IHC: 1:20-1:200 | ||
| Molecular weight | N/A | ||
| Conjugate | Unconjugated | ||
| Immunogen | Recombinant Human E3 ubiquitin-protein ligase TRIP12 protein (1-240AA) | ||
| Specificity | TRIP12 antibody detects endogenous level of TRIP12 protein | ||
| Storage | Store at +4°C for short term (1 week), for long term aliquote and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles, with each freeze and thaw cycle an antibody can lose half of its binding activity. | ||
|---|---|---|---|
| Clonality | Polyclonal | ||
| Isotype | IgG | ||
| Clone ID | N/A | ||
| Concentration | Concentration can vary between different batches. | ||
| Storage buffer | Phosphate-buffered saline (pH 7.3) containing 0.02% Sodium Azide (NaN3) and 50% Glycerol. | ||
| Formulation | Liquid | ||
| Purification | This antibody is immunogen affinity purified. | ||
| Handling | This product contains sodium azide (NaN3) as preservative, please take appropriate care when handling this product. | ||
| Reactivity life | 12 months when stored properly according to instructions (provided antibody remains sterile). | ||
Product Details
© 2020 Imugex All Rights Reserved